glp-1 usage statistics Receptor Agonist Market Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 The Multi-Sector Impacts of GLP-1RA

Vomiting : Some may experience this, particularly when first starting treatment

Food and Drug Administration (FDA) has declared an end to the shortage of these GLP-1 medications, resulting in the discontinuation of compounded versions that many patients have relied on

Should I Start a Drug Now if I May Lose Access Later

This, however, does not apply to other GLP-1RAs approved for the treatment of T2DM, including the same liraglutide (Victoza) and semaglutide (Ozempic or Rybelsus) at lower dosages, prompting several stakeholders to request an updated guidance 232 and more caution in media enthusiasm 233

While it also presents gastrointestinal side effects, its profile appears significantly more manageable and cleaner regarding liver safety signals, demonstrating a better balance of efficacy and tolerability